{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 155607, "items": [{"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T23:02:31Z", "timestamp": 1574550151079}, "reference-count": 99, "publisher": "Informa Healthcare", "issue": "11", "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["Expert Opinion on Drug Safety"], "published-print": {"date-parts": [[2014, 11]]}, "DOI": "10.1517/14740338.2014.966686", "type": "journal-article", "created": {"date-parts": [[2014, 10, 1]], "date-time": "2014-10-01T09:49:34Z", "timestamp": 1412156974000}, "page": "1483-1499", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 10, "title": ["Safety of antiandrogen therapy for treating prostate cancer"], "prefix": "10.1517", "volume": "13", "author": [{"given": "Francesco", "family": "Ricci", "sequence": "first", "affiliation": []}, {"given": "Giulia", "family": "Buzzatti", "sequence": "additional", "affiliation": []}, {"given": "Alessandra", "family": "Rubagotti", "sequence": "additional", "affiliation": []}, {"given": "Francesco", "family": "Boccardo", "sequence": "additional", "affiliation": []}], "member": "3197", "published-online": {"date-parts": [[2014, 10]]}, "reference": [{"key": "CIT0001", "DOI": "10.3322/caac.21208", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1200/JCO.2010.31.2330", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1093/jnci/94.13.981", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1093/jnci/djp262", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1200/JCO.2004.10.062", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1200/JCO.2007.13.9881", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1200/JCO.2003.11.023", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1016/j.ijrobp.2004.08.047", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1016/S1470-2045(06)70700-8", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1155/2012/691380", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "CIT0011", "first-page": "1", "volume": "14", "author": "Lepor H", "year": "2012", "journal-title": "Rev Urol"}, {"key": "CIT0012", "DOI": "10.1016/S0022-5347(05)00034-0", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1111/j.1442-2042.2012.02997.x", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1016/j.eururo.2013.11.002", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "author": "Klotz L", "year": "2014", "journal-title": "Eur Urol"}, {"key": "CIT0016", "DOI": "10.1016/j.mce.2011.07.025", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1210/me.2009-0310", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.4161/cc.9.3.11045", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1007/s00432-006-0133-5", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1158/0008-5472.CAN-08-0249", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1158/0008-5472.CAN-06-3332", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "author": "Schmitt B", "volume": "2", "first-page": "CD001526", "year": "2000", "journal-title": "Cochrane Database Syst Rev"}, {"key": "CIT0023", "DOI": "10.1016/S0090-4295(00)01086-4", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1002/cncr.24393", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1111/j.1365-2265.1994.tb02585.x", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.1111/j.1464-410X.2010.09726.x", "doi-asserted-by": "publisher"}, {"issue": "12", "key": "CIT0027", "doi-asserted-by": "crossref", "first-page": "1471", "DOI": "10.6004/jnccn.2013.0174", "volume": "11", "author": "Mohler JL", "year": "2013", "journal-title": "J Natl Compr Canc Netw"}, {"key": "CIT0028", "DOI": "10.7326/0003-4819-132-7-200004040-00009", "doi-asserted-by": "publisher"}, {"issue": "7", "key": "CIT0029", "doi-asserted-by": "crossref", "first-page": "2027", "DOI": "10.1200/JCO.1999.17.7.2027", "volume": "17", "author": "Boccardo F", "year": "1999", "journal-title": "J Clin Oncol"}, {"key": "CIT0030", "DOI": "10.1016/S0022-5347(05)67032-2", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1159/000019634", "doi-asserted-by": "publisher"}, {"key": "CIT0032", "DOI": "10.1097/PPO.0b013e318282635a", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1056/NEJMoa1207506", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.1200/JCO.2013.50.1684", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.1056/NEJMoa1014618", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1200/JCO.2008.20.0642", "doi-asserted-by": "publisher"}, {"issue": "12", "key": "CIT0037", "doi-asserted-by": "crossref", "first-page": "2317", "DOI": "10.1038/sj.bjc.6601879", "volume": "90", "author": "O\u2019Donnell A", "year": "2004", "journal-title": "Br J Cancer"}, {"key": "CIT0038", "DOI": "10.1056/NEJMoa1209096", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1210/jc.2011-2189", "doi-asserted-by": "publisher"}, {"key": "CIT0040", "DOI": "10.1056/NEJMoa1405095", "doi-asserted-by": "publisher"}, {"key": "CIT0041", "DOI": "10.1016/S1470-2045(14)70129-9", "doi-asserted-by": "publisher"}, {"key": "CIT0042", "DOI": "10.1186/1741-7015-10-96", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "CIT0043", "first-page": "283", "volume": "80", "author": "Chatelain C", "year": "1997", "journal-title": "Br J Urol"}, {"key": "CIT0044", "DOI": "10.1111/j.1464-410X.2010.09319.x", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.1200/JCO.2005.12.013", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "DOI": "10.1038/sj.pcan.4500782", "doi-asserted-by": "publisher"}, {"key": "CIT0047", "DOI": "10.1016/j.eururo.2009.05.019", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "CIT0048", "doi-asserted-by": "crossref", "first-page": "14", "DOI": "10.1159/000474543", "volume": "31", "author": "Kaisary AV", "year": "1997", "journal-title": "Eur Urol"}, {"key": "CIT0049", "author": "Decensi AU", "volume": "146", "first-page": "377", "year": "1991", "journal-title": "J Urol", "DOI": "10.1016/S0022-5347(17)37799-6", "doi-asserted-by": "crossref"}, {"key": "CIT0050", "DOI": "10.1016/j.urolonc.2007.05.014", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "CIT0051", "first-page": "391", "volume": "32", "author": "Boccon-Gibod L", "year": "1997", "journal-title": "Eur Urol"}, {"key": "CIT0052", "DOI": "10.1016/j.eururo.2003.11.016", "doi-asserted-by": "publisher"}, {"key": "CIT0053", "DOI": "10.1016/j.eururo.2003.10.013", "doi-asserted-by": "publisher"}, {"key": "CIT0054", "DOI": "10.1097/01.ju.0000106835.60202.81", "doi-asserted-by": "publisher"}, {"key": "CIT0055", "DOI": "10.1093/jnci/81.23.1839", "doi-asserted-by": "publisher"}, {"key": "CIT0056", "DOI": "10.1016/S0959-8049(05)80293-X", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "CIT0057", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1159/000463979", "volume": "18", "author": "Iversen P", "year": "1990", "journal-title": "Eur Urol"}, {"key": "CIT0058", "DOI": "10.1159/000019546", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "CIT0059", "first-page": "954", "volume": "269", "author": "Fau D", "year": "1994", "journal-title": "J Pharmacol Exp Ther"}, {"key": "CIT0060", "DOI": "10.1248/bpb.30.739", "doi-asserted-by": "publisher"}, {"key": "CIT0061", "DOI": "10.1159/000081585", "doi-asserted-by": "publisher"}, {"issue": "6", "key": "CIT0062", "first-page": "501", "volume": "15", "author": "Boccardo F", "year": "1991", "journal-title": "Cancer Detect Prev"}, {"key": "CIT0063", "DOI": "10.1097/00005392-199707000-00051", "doi-asserted-by": "publisher"}, {"key": "CIT0064", "author": "B\u00e9land G", "volume": "18", "first-page": "75", "year": "1991", "journal-title": "Urol Clin North Am"}, {"key": "CIT0065", "DOI": "10.2165/00002512-199303010-00002", "doi-asserted-by": "publisher"}, {"key": "CIT0066", "DOI": "10.1111/j.1464-410X.2006.06275.x", "doi-asserted-by": "publisher"}, {"key": "CIT0067", "DOI": "10.1038/sj.pcan.4500531", "doi-asserted-by": "publisher"}, {"key": "CIT0068", "DOI": "10.1016/S0090-4295(96)00355-X", "doi-asserted-by": "publisher"}, {"key": "CIT0069", "DOI": "10.1007/s10147-011-0239-x", "doi-asserted-by": "publisher"}, {"key": "CIT0070", "DOI": "10.2165/00003088-200443130-00003", "doi-asserted-by": "publisher"}, {"key": "CIT0071", "DOI": "10.1016/j.eururo.2006.08.043", "doi-asserted-by": "publisher"}, {"key": "CIT0072", "DOI": "10.1016/S0140-6736(10)60172-9", "doi-asserted-by": "publisher"}, {"key": "CIT0073", "DOI": "10.1002/pros.21263", "doi-asserted-by": "publisher"}, {"key": "CIT0074", "DOI": "10.1093/annonc/mdt571", "doi-asserted-by": "publisher"}, {"key": "CIT0075", "DOI": "10.1002/cncr.28518", "doi-asserted-by": "publisher"}, {"key": "CIT0076", "DOI": "10.1016/j.eururo.2013.06.042", "doi-asserted-by": "publisher"}, {"key": "CIT0077", "DOI": "10.1158/0008-5472.CAN-11-3948", "doi-asserted-by": "publisher"}, {"key": "CIT0078", "DOI": "10.1038/aja.2011.106", "doi-asserted-by": "publisher"}, {"key": "CIT0079", "DOI": "10.1016/j.critrevonc.2013.01.006", "doi-asserted-by": "publisher"}, {"key": "CIT0080", "DOI": "10.1159/000052339", "doi-asserted-by": "publisher"}, {"key": "CIT0081", "DOI": "10.1016/j.maturitas.2009.10.017", "doi-asserted-by": "publisher"}, {"key": "CIT0082", "DOI": "10.1002/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2", "doi-asserted-by": "publisher"}, {"key": "CIT0083", "DOI": "10.1080/13685530802172438", "doi-asserted-by": "publisher"}, {"key": "CIT0084", "DOI": "10.1016/j.pbb.2004.04.019", "doi-asserted-by": "publisher"}, {"key": "CIT0085", "DOI": "10.1046/j.1464-410X.2002.02917.x", "doi-asserted-by": "publisher"}, {"key": "CIT0086", "DOI": "10.1111/j.1464-410X.2004.04763.x", "doi-asserted-by": "publisher"}, {"key": "CIT0087", "DOI": "10.1038/ncpuro0995", "doi-asserted-by": "publisher"}, {"key": "CIT0088", "DOI": "10.1210/rp.57.1.385", "doi-asserted-by": "publisher"}, {"key": "CIT0089", "DOI": "10.1111/j.1464-410X.2009.08483.x", "doi-asserted-by": "publisher"}, {"key": "CIT0090", "DOI": "10.1016/j.jsbmb.2006.07.006", "doi-asserted-by": "publisher"}, {"key": "CIT0091", "DOI": "10.1200/JCO.2006.06.2497", "doi-asserted-by": "publisher"}, {"key": "CIT0092", "DOI": "10.1111/j.1365-2265.2005.02339.x", "doi-asserted-by": "publisher"}, {"key": "CIT0093", "DOI": "10.1210/jc.2004-1158", "doi-asserted-by": "publisher"}, {"key": "CIT0094", "DOI": "10.1200/JCO.2006.05.9741", "doi-asserted-by": "publisher"}, {"issue": "5", "key": "CIT0095", "first-page": "1060", "volume": "100", "author": "Derweesh IH", "year": "2007", "journal-title": "BJU Int"}, {"key": "CIT0096", "DOI": "10.1001/jama.2011.1745", "doi-asserted-by": "publisher"}, {"key": "CIT0097", "DOI": "10.1111/j.1464-410X.2006.06416.x", "doi-asserted-by": "publisher"}, {"key": "CIT0098", "DOI": "10.1111/j.1365-2265.2007.02999.x", "doi-asserted-by": "publisher"}, {"key": "CIT0099", "DOI": "10.1093/jnci/djp404", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Drug Safety"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1517/14740338.2014.966686", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 15]], "date-time": "2019-08-15T18:09:42Z", "timestamp": 1565892582000}, "score": 46.685463, "issued": {"date-parts": [[2014, 10]]}, "references-count": 99, "journal-issue": {"published-online": {"date-parts": [[2014, 10, 23]]}, "published-print": {"date-parts": [[2014, 11]]}, "issue": "11"}, "alternative-id": ["10.1517/14740338.2014.966686"], "URL": "http://dx.doi.org/10.1517/14740338.2014.966686", "relation": {"cites": []}, "ISSN": ["1474-0338", "1744-764X"], "issn-type": [{"value": "1474-0338", "type": "print"}, {"value": "1744-764X", "type": "electronic"}], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieds20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieds20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T19:49:54Z", "timestamp": 1574797794709}, "reference-count": 4, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 9, 1]], "date-time": "2017-09-01T00:00:00Z", "timestamp": 1504224000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.fr", "clinicalkey.com.au", "europeanurology.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Urology"], "published-print": {"date-parts": [[2017, 9]]}, "DOI": "10.1016/j.eururo.2017.06.018", "type": "journal-article", "created": {"date-parts": [[2017, 6, 21]], "date-time": "2017-06-21T08:23:38Z", "timestamp": 1498033418000}, "page": "471-472", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer"], "prefix": "10.1016", "volume": "72", "author": [{"given": "David", "family": "D\u2019Andrea", "sequence": "first", "affiliation": []}, {"given": "Shahrokh F.", "family": "Shariat", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Urology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0302283817305134?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0302283817305134?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 8, 31]], "date-time": "2018-08-31T15:52:19Z", "timestamp": 1535730739000}, "score": 31.938877, "issued": {"date-parts": [[2017, 9]]}, "references-count": 4, "journal-issue": {"published-print": {"date-parts": [[2017, 9]]}, "issue": "3"}, "alternative-id": ["S0302283817305134"], "URL": "http://dx.doi.org/10.1016/j.eururo.2017.06.018", "ISSN": ["0302-2838"], "issn-type": [{"value": "0302-2838", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer", "name": "articletitle", "label": "Article Title"}, {"value": "European Urology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.eururo.2017.06.018", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "simple-article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:59:25Z", "timestamp": 1575305965537}, "reference-count": 58, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 6, 1]], "date-time": "2005-06-01T00:00:00Z", "timestamp": 1117584000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Prostate Cancer"], "published-print": {"date-parts": [[2005, 6]]}, "DOI": "10.3816/cgc.2005.n.010", "type": "journal-article", "created": {"date-parts": [[2008, 9, 11]], "date-time": "2008-09-11T01:07:44Z", "timestamp": 1221095264000}, "page": "38-44", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Treating the Biochemical Recurrence of Prostate Cancer After Definitive Primary Therapy"], "prefix": "10.3816", "volume": "4", "author": [{"given": "John F.", "family": "Ward", "sequence": "first", "affiliation": []}, {"given": "Judd W.", "family": "Moul", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Prostate Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S154003521170097X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S154003521170097X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T23:00:04Z", "timestamp": 1557788404000}, "score": 30.124962, "issued": {"date-parts": [[2005, 6]]}, "references-count": 58, "journal-issue": {"published-print": {"date-parts": [[2005, 6]]}, "issue": "1"}, "alternative-id": ["S154003521170097X"], "URL": "http://dx.doi.org/10.3816/cgc.2005.n.010", "ISSN": ["1540-0352"], "issn-type": [{"value": "1540-0352", "type": "print"}], "subject": ["Urology", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T05:11:08Z", "timestamp": 1574399468944}, "reference-count": 0, "publisher": "American Chemical Society (ACS)", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J. Chem. Educ."], "published-print": {"date-parts": [[2003, 12]]}, "DOI": "10.1021/ed080p1496", "type": "journal-article", "created": {"date-parts": [[2009, 12, 17]], "date-time": "2009-12-17T22:21:31Z", "timestamp": 1261088491000}, "page": "1496", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Featured Molecules: Antiandrogen Prostate Cancer Drugs"], "prefix": "10.1021", "volume": "80", "author": [{"given": "William F.", "family": "Coleman", "sequence": "first", "affiliation": []}], "member": "316", "container-title": ["Journal of Chemical Education"], "language": "en", "link": [{"URL": "https://pubs.acs.org/doi/pdf/10.1021/ed080p1496", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 8]], "date-time": "2019-10-08T22:54:16Z", "timestamp": 1570575256000}, "score": 27.302397, "issued": {"date-parts": [[2003, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2003, 12]]}, "issue": "12"}, "alternative-id": ["10.1021/ed080p1496"], "URL": "http://dx.doi.org/10.1021/ed080p1496", "ISSN": ["0021-9584", "1938-1328"], "issn-type": [{"value": "0021-9584", "type": "print"}, {"value": "1938-1328", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T15:21:11Z", "timestamp": 1574868071056}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2017, 11, 15]]}, "DOI": "10.1158/1538-7445.newfront17-ia22", "type": "proceedings-article", "created": {"date-parts": [[2017, 12, 1]], "date-time": "2017-12-01T14:38:08Z", "timestamp": 1512139088000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract IA22: Emerging signaling pathways in prostate cancer therapy"], "prefix": "10.1158", "author": [{"given": "Luiz F.", "family": "Zerbini", "sequence": "first", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2017, 11, 14]]}, "event": {"name": "Abstracts: AACR International Conference: New Frontiers in Cancer Research; January 18-22, 2017; Cape Town, South Africa"}, "container-title": ["Prostate Cancer"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.NEWFRONT17-IA22", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T17:58:22Z", "timestamp": 1558202302000}, "score": 26.862055, "issued": {"date-parts": [[2017, 11, 14]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.NEWFRONT17-IA22"], "URL": "http://dx.doi.org/10.1158/1538-7445.newfront17-ia22"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T09:00:08Z", "timestamp": 1574240408593}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "9", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Anti-Cancer Drugs"], "published-print": {"date-parts": [[1999, 10]]}, "DOI": "10.1097/00001813-199910000-00001", "type": "journal-article", "created": {"date-parts": [[2006, 10, 30]], "date-time": "2006-10-30T11:54:25Z", "timestamp": 1162209265000}, "page": "791-796", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first-to second-generation antiandrogen"], "prefix": "10.1097", "volume": "10", "author": [{"given": "Michael F", "family": "Sarosdy", "sequence": "first", "affiliation": []}], "member": "276", "container-title": ["Anti-Cancer Drugs"], "language": "en", "deposited": {"date-parts": [[2018, 2, 8]], "date-time": "2018-02-08T22:05:01Z", "timestamp": 1518127501000}, "score": 26.438929, "subtitle": [""], "issued": {"date-parts": [[1999, 10]]}, "references-count": 0, "journal-issue": {"issue": "9"}, "URL": "http://dx.doi.org/10.1097/00001813-199910000-00001", "ISSN": ["0959-4973"], "issn-type": [{"value": "0959-4973", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T10:06:13Z", "timestamp": 1574417173549}, "publisher-location": "Oxford, UK", "reference-count": 13, "publisher": "Wiley-Blackwell", "isbn-type": [{"value": "9781405196499", "type": "print"}, {"value": "9781444346893", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9781444346893.ch10", "type": "book-chapter", "created": {"date-parts": [[2011, 11, 10]], "date-time": "2011-11-10T12:28:52Z", "timestamp": 1320928132000}, "page": "85-97", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Energies for Focal Ablation: Cryoablation"], "prefix": "10.1002", "author": [{"given": "John F.", "family": "Ward", "sequence": "first", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 11, 10]]}, "reference": [{"key": "10.1002/9781444346893.ch10-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1016/S0140-6736(02)89874-9", "article-title": "Practical illustrations of the remedial efficacy of a very low or anaesthetic temperature. I. In Cancer", "volume": "2", "author": "Arnott", "year": "1850", "journal-title": "Lancet"}, {"key": "10.1002/9781444346893.ch10-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "259", "DOI": "10.1097/00005053-196109000-00013", "article-title": "Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues", "volume": "133", "author": "Cooper", "year": "1961", "journal-title": "J Nerv Ment Dis"}, {"key": "10.1002/9781444346893.ch10-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1056/NEJM196601062740103", "article-title": "Application of cryogenic surgery to resection of parenchymal organs", "volume": "274", "author": "Cooper", "year": "1966", "journal-title": "NEJM"}, {"key": "10.1002/9781444346893.ch10-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "220", "DOI": "10.1016/0090-4295(74)90340-9", "article-title": "Closed perineal cryosurgery in prostatic cancer. New probe and technique", "volume": "4", "author": "Megalli", "year": "1974", "journal-title": "Urology"}, {"key": "10.1002/9781444346893.ch10-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "629", "DOI": "10.1148/radiology.168.3.3043544", "article-title": "US characteristics of frozen prostate", "volume": "168", "author": "Onik", "year": "1988", "journal-title": "Radiology"}, {"key": "10.1002/9781444346893.ch10-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "896", "DOI": "10.1038/sj.bjc.6603341", "article-title": "Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity", "volume": "95", "author": "den Brok", "year": "2006", "journal-title": "BJC"}, {"key": "10.1002/9781444346893.ch10-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1117", "DOI": "10.1016/j.urology.2007.02.047", "article-title": "Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer", "volume": "69", "author": "Lambert", "year": "2007", "journal-title": "Urology"}, {"key": "10.1002/9781444346893.ch10-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "688", "DOI": "10.1089/end.2006.20.688", "article-title": "Focal Prostate Cryoablation: Initial Results Show Cancer Control and Potency Preservation", "volume": "20", "author": "Bahn", "year": "2006", "journal-title": "J Endourology"}, {"key": "10.1002/9781444346893.ch10-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "500", "DOI": "10.1016/j.urolonc.2008.03.004", "article-title": "The \u201cmale lumpectomy\u201d: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up", "volume": "26", "author": "Onik", "year": "2008", "journal-title": "Urol Oncol"}, {"key": "10.1002/9781444346893.ch10-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.1097/MOU.0b013e3282f9b3a5", "article-title": "Focal therapy for prostate cancer", "volume": "18", "author": "Polascik", "year": "2008", "journal-title": "Curr Opin Urol"}, {"key": "10.1002/9781444346893.ch10-BIB11|cit11", "author": "Ward", "year": "2009", "article-title": "Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy", "journal-title": "BJUI", "DOI": "10.1111/j.1464-410X.2009.08359.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/9781444346893.ch10-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "365", "DOI": "10.1177/153303460400300406", "article-title": "The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review", "volume": "3", "author": "Onik", "year": "2004", "journal-title": "Technol Cancer Res Treat"}, {"issue": "6", "key": "10.1002/9781444346893.ch10-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "1258", "DOI": "10.1016/j.urology.2009.10.044", "article-title": "Classification System: Organ Preserving Treatment for Prostate Cancer", "volume": "75", "author": "Ward", "year": "2010", "journal-title": "Urology"}], "container-title": ["Focal Therapy in Prostate Cancer"], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T09:28:45Z", "timestamp": 1497950925000}, "score": 25.707153, "issued": {"date-parts": [[2011, 11, 10]]}, "ISBN": ["9781444346893", "9781405196499"], "references-count": 13, "URL": "http://dx.doi.org/10.1002/9781444346893.ch10", "relation": {"cites": []}}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T23:28:17Z", "timestamp": 1574810897599}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2007, 2, 1]]}, "DOI": "10.21236/ada470022", "type": "report", "created": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T16:25:18Z", "timestamp": 1500049518000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Microtubule-Targeting Therapy for Prostate Cancer"], "prefix": "10.21236", "author": [{"given": "George F.", "family": "Atweh", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T16:25:19Z", "timestamp": 1500049519000}, "score": 25.186144, "subtitle": [""], "issued": {"date-parts": [[2007, 2, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada470022"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T10:06:13Z", "timestamp": 1574417173530}, "publisher-location": "Oxford, UK", "reference-count": 20, "publisher": "Wiley-Blackwell", "isbn-type": [{"value": "9781405196499", "type": "print"}, {"value": "9781444346893", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9781444346893.ch8", "type": "book-chapter", "created": {"date-parts": [[2011, 11, 10]], "date-time": "2011-11-10T12:28:52Z", "timestamp": 1320928132000}, "page": "66-74", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Localization of Cancer within the Gland: Diffusion-Weighted Magnetic Resonance Imaging of the Prostate"], "prefix": "10.1002", "author": [{"given": "Sophie F.", "family": "Riches", "sequence": "first", "affiliation": []}, {"given": "Nina", "family": "Tunariu", "sequence": "additional", "affiliation": []}, {"given": "Nandita M.", "family": "deSouza", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 11, 10]]}, "reference": [{"issue": "6", "key": "10.1002/9781444346893.ch8-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "1163", "DOI": "10.1016/j.eururo.2006.06.025", "article-title": "How good is MRI at detecting and characterising cancer within the prostate", "volume": "50", "author": "Kirkham", "year": "2006", "journal-title": "Eur Urol"}, {"issue": "7", "key": "10.1002/9781444346893.ch8-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "883", "DOI": "10.1111/j.1464-410X.2008.08130.x", "article-title": "Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer", "volume": "103", "author": "Zelhof", "year": "2009", "journal-title": "BJUInt"}, {"issue": "2", "key": "10.1002/9781444346893.ch8-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.2463/mrms.7.93", "article-title": "High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio", "volume": "7", "author": "Kitajima", "year": "2008", "journal-title": "Magn Reson Med Sci"}, {"issue": "5", "key": "10.1002/9781444346893.ch8-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "801", "DOI": "10.1002/jmri.1880060514", "article-title": "A solid reusable endorectal receiver coil for magnetic resonance imaging of the prostate: design, use, and comparison with an inflatable endorectal coil", "volume": "6", "author": "deSouza", "year": "1996", "journal-title": "J Magn Reson Imaging"}, {"issue": "7", "key": "10.1002/9781444346893.ch8-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "774", "DOI": "10.1016/j.crad.2008.02.001", "article-title": "Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumor aggressiveness in localized prostate cancer", "volume": "63", "author": "deSouza", "year": "2008", "journal-title": "Clin Radiol"}, {"issue": "950", "key": "10.1002/9781444346893.ch8-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "90", "DOI": "10.1259/bjr/24232319", "article-title": "Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules", "volume": "80", "author": "deSouza", "year": "2007", "journal-title": "Br J Radiol"}, {"issue": "6", "key": "10.1002/9781444346893.ch8-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1054", "DOI": "10.1002/mrm.1298", "article-title": "Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate", "volume": "46", "author": "Gibbs", "year": "2001", "journal-title": "Magn Reson Med"}, {"issue": "4", "key": "10.1002/9781444346893.ch8-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "654", "DOI": "10.1002/jmri.20159", "article-title": "Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue", "volume": "20", "author": "Hosseinzadeh", "year": "2004", "journal-title": "J Magn Reson Imaging"}, {"issue": "3", "key": "10.1002/9781444346893.ch8-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1002/jmri.20251", "article-title": "Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate", "volume": "21", "author": "Sato", "year": "2005", "journal-title": "JMagn Reson Imaging"}, {"issue": "2", "key": "10.1002/9781444346893.ch8-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "196", "DOI": "10.1002/jmri.10139", "article-title": "In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging", "volume": "16", "author": "Issa", "year": "2002", "journal-title": "J Magn Reson Imaging"}, {"issue": "1", "key": "10.1002/9781444346893.ch8-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.2214/AJR.05.2198", "article-title": "Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection", "volume": "188", "author": "Reinsberg", "year": "2007", "journal-title": "AJR Am J Roentgenol"}, {"issue": "2", "key": "10.1002/9781444346893.ch8-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "149", "DOI": "10.1097/01.rct.0000156396.13522.f2", "article-title": "Diffusion-weighted imaging of prostate cancer", "volume": "29", "author": "Shimofusa", "year": "2005", "journal-title": "J Comput Assist Tomogr"}, {"issue": "6", "key": "10.1002/9781444346893.ch8-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "695", "DOI": "10.1080/02841850701349257", "article-title": "Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection", "volume": "48", "author": "Morgan", "year": "2007", "journal-title": "Acta Radiol"}, {"issue": "1", "key": "10.1002/9781444346893.ch8-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "145", "DOI": "10.1148/radiol.2501080207", "article-title": "Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study", "volume": "250", "author": "Lim", "year": "2009", "journal-title": "Radiology"}, {"issue": "2", "key": "10.1002/9781444346893.ch8-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "323", "DOI": "10.2214/AJR.07.2211", "article-title": "Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer", "volume": "189", "author": "Haider", "year": "2007", "journal-title": "Am J Roentgenol"}, {"issue": "950", "key": "10.1002/9781444346893.ch8-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "90", "DOI": "10.1259/bjr/24232319", "article-title": "Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules", "volume": "80", "author": "Desouza", "year": "2007", "journal-title": "Br J Radiol"}, {"issue": "2", "key": "10.1002/9781444346893.ch8-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "449", "DOI": "10.1148/radiol.2523081423", "article-title": "Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume", "volume": "252", "author": "Mazaheri", "year": "2009", "journal-title": "Radiology"}, {"issue": "4", "key": "10.1002/9781444346893.ch8-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "452", "DOI": "10.1111/j.1464-410X.2008.07633.x", "article-title": "Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound", "volume": "102", "author": "Cirillo", "year": "2008", "journal-title": "BJU Int"}, {"key": "10.1002/9781444346893.ch8-BIB19|cit19", "unstructured": "Chapman A Evaluation of the prostate after treatment with high-intensity focussed ultrasound (HIFU) therapy using whole prostate diffusion weighted imaging (DWI) analysis Proceedings 16th Scientific Meeting, International Society for Magnetic Resonance in Medicine; 2008"}, {"issue": "5", "key": "10.1002/9781444346893.ch8-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "1180", "DOI": "10.2214/AJR.07.2924", "article-title": "MRI techniques for prediction of local tumor progression after highintensity focusedultrasonic ablation of prostate cancer", "volume": "190", "author": "Kim", "year": "2008", "journal-title": "AJR Am J Roentgenol"}], "container-title": ["Focal Therapy in Prostate Cancer"], "deposited": {"date-parts": [[2019, 6, 19]], "date-time": "2019-06-19T10:50:10Z", "timestamp": 1560941410000}, "score": 24.555628, "issued": {"date-parts": [[2011, 11, 10]]}, "ISBN": ["9781444346893", "9781405196499"], "references-count": 20, "URL": "http://dx.doi.org/10.1002/9781444346893.ch8", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T14:23:43Z", "timestamp": 1574519023505}, "publisher-location": "Totowa, NJ", "reference-count": 16, "publisher": "Humana Press", "isbn-type": [{"value": "9781627031813", "type": "print"}, {"value": "9781627031820", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2013]]}, "DOI": "10.1007/978-1-62703-182-0_17", "type": "book-chapter", "created": {"date-parts": [[2012, 11, 30]], "date-time": "2012-11-30T22:05:03Z", "timestamp": 1354313103000}, "page": "237-244", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Prostate Focal Therapy: Definitions and Common Terminology"], "prefix": "10.1007", "author": [{"given": "John F.", "family": "Ward", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 11, 3]]}, "reference": [{"issue": "1", "key": "17_CR00171", "doi-asserted-by": "publisher", "first-page": "109", "DOI": "10.1016/S0090-4295(02)01643-6", "volume": "60", "author": "G Onik", "year": "2002", "unstructured": "Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal \u201cnerve-sparing\u201d cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60(1):109\u201314.", "journal-title": "Urology"}, {"issue": "9", "key": "17_CR00172", "doi-asserted-by": "publisher", "first-page": "688", "DOI": "10.1089/end.2006.20.688", "volume": "20", "author": "DK Bahn", "year": "2006", "unstructured": "Bahn DK, Silverman P, Lee F, et al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol. 2006;20(9):688\u201392.", "journal-title": "J Endourol"}, {"key": "17_CR00173", "doi-asserted-by": "publisher", "first-page": "500", "DOI": "10.1016/j.urolonc.2008.03.004", "volume": "26", "author": "G Onik", "year": "2008", "unstructured": "Onik G, Vaughan D, lotenfoe R. The \u201cmale lumpectomy\u201d: Focal therapy for prostate cancer using cryoablation results in 48 patients with a least 2-year follow-up. Urol Oncol. 2008;26:500\u20135.", "journal-title": "Urol Oncol"}, {"key": "17_CR00174", "doi-asserted-by": "publisher", "first-page": "1648", "DOI": "10.1111/j.1464-410X.2011.10578.x", "volume": "109", "author": "JF Ward", "year": "2012", "unstructured": "Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012;109:1648\u201354.", "journal-title": "BJU Int"}, {"issue": "6", "key": "17_CR00175", "doi-asserted-by": "publisher", "first-page": "1258", "DOI": "10.1016/j.urology.2009.10.044", "volume": "75", "author": "JF Ward", "year": "2010", "unstructured": "Ward JF, Jones JS. Classification system: organ preserving treatment for prostate cancer. Urology. 2010;75(6):1258\u201360.", "journal-title": "Urology"}, {"issue": "4", "key": "17_CR00176", "doi-asserted-by": "publisher", "first-page": "520", "DOI": "10.1089/end.2005.19.520", "volume": "19", "author": "NK Janzen", "year": "2005", "unstructured": "Janzen NK, Han K-R, Perry KT, et al. Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J Endourol. 2005;19(4):520\u20135.", "journal-title": "J Endourol"}, {"key": "17_CR00177", "doi-asserted-by": "publisher", "first-page": "1210", "DOI": "10.1111/j.1464-410X.2010.09711.x", "volume": "107", "author": "AJ Costello", "year": "2011", "unstructured": "Costello AJ, Dowdle BW, Namdarian B, Pedersen J, Murphy DG. Immunohistochemical study of the cavernous nerves in the periprostatic region. BJU Int. 2011;107:1210\u20135.", "journal-title": "BJU Int"}, {"key": "17_CR00178", "doi-asserted-by": "publisher", "first-page": "1135", "DOI": "10.1016/j.eururo.2008.08.051", "volume": "55", "author": "J Davis", "year": "2009", "unstructured": "Davis J, Chang D, Chevray P, et al. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009;55:1135\u201343.", "journal-title": "Eur Urol"}, {"issue": "4", "key": "17_CR00179", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1111/j.1464-410X.2009.08359.x", "volume": "104", "author": "JF Ward", "year": "2009", "unstructured": "Ward JF, Nakanishi H, Pisters LL, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int. 2009;104(4):490\u20137.", "journal-title": "BJU Int"}, {"key": "17_CR001710", "doi-asserted-by": "publisher", "first-page": "192", "DOI": "10.1093/jjco/hym173", "volume": "38", "author": "S Muto", "year": "2008", "unstructured": "Muto S, Yoshii T, Saito K. Focal therapy with \u00adhigh-intensity- focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38:192\u20139.", "journal-title": "Jpn J Clin Oncol"}, {"issue": "3", "key": "17_CR001711", "doi-asserted-by": "publisher", "first-page": "283", "DOI": "10.1097/MOU.0b013e32832a2c4a", "volume": "19", "author": "AH Hou", "year": "2009", "unstructured": "Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review. Curr Opin Urol. 2009;19(3):283\u20139.", "journal-title": "Curr Opin Urol"}, {"issue": "5", "key": "17_CR001712", "doi-asserted-by": "publisher", "first-page": "506", "DOI": "10.1016/j.urolonc.2008.03.005", "volume": "26", "author": "G Onik", "year": "2008", "unstructured": "Onik G, Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol. 2008;26(5):506\u201310.", "journal-title": "Urol Oncol"}, {"issue": "1", "key": "17_CR001713", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.1016/j.eururo.2010.03.006", "volume": "58", "author": "O Raz", "year": "2010", "unstructured": "Raz O, Haider MA, Davidson SRH, et al. Real-time magnetic resonance imaging-guided focal laser \u00adtherapy in patients with low-risk prostate cancer. Eur Urol. 2010;58(1):173\u20137.", "journal-title": "Eur Urol"}, {"issue": "4", "key": "17_CR001714", "doi-asserted-by": "publisher", "first-page": "1514", "DOI": "10.1016/j.juro.2010.05.091", "volume": "184", "author": "RJ Stafford", "year": "2010", "unstructured": "Stafford RJ, Shetty AM, Elliott AM, et al. Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol. 2010;184(4):1514\u201320.", "journal-title": "J Urol"}, {"issue": "5", "key": "17_CR001715", "doi-asserted-by": "publisher", "first-page": "556", "DOI": "10.1111/j.1464-410X.2008.07753.x", "volume": "102", "author": "J Trachtenberg", "year": "2008", "unstructured": "Trachtenberg J, Weersink RA, Davidson SRH, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008;102(5):556\u201362.", "journal-title": "BJU Int"}, {"issue": "5", "key": "17_CR001716", "doi-asserted-by": "publisher", "first-page": "546", "DOI": "10.1111/j.1464-410X.2008.07832.x", "volume": "102", "author": "II Megwalu", "year": "2008", "unstructured": "Megwalu II, Ferguson GG, Wei JT, et al. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int. 2008;102(5):546\u201350.", "journal-title": "BJU Int"}], "container-title": ["Imaging and Focal Therapy of Early Prostate Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-1-62703-182-0_17", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T11:04:40Z", "timestamp": 1557399880000}, "score": 24.163622, "issued": {"date-parts": [[2012, 11, 3]]}, "ISBN": ["9781627031813", "9781627031820"], "references-count": 16, "URL": "http://dx.doi.org/10.1007/978-1-62703-182-0_17", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T22:13:45Z", "timestamp": 1574374425219}, "publisher-location": "Basel", "reference-count": 0, "publisher": "KARGER", "isbn-type": [{"value": "9783805585248", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2008]]}, "DOI": "10.1159/000139879", "type": "book-chapter", "created": {"date-parts": [[2008, 6, 11]], "date-time": "2008-06-11T13:29:38Z", "timestamp": 1213190978000}, "page": "58-67", "source": "Crossref", "is-referenced-by-count": 6, "title": ["Lymphadenectomy in Prostate Cancer"], "prefix": "10.1159", "author": [{"given": "A.", "family": "Winter", "sequence": "first", "affiliation": []}, {"given": "F.", "family": "Wawroschek", "sequence": "additional", "affiliation": []}], "member": "127", "container-title": ["Frontiers of Radiation Therapy and Oncology", "Controversies in the Treatment of Prostate Cancer"], "link": [{"URL": "http://www.karger.com/Article/Pdf/139879", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 10, 25]], "date-time": "2017-10-25T17:48:37Z", "timestamp": 1508953717000}, "score": 23.958775, "issued": {"date-parts": [[2008]]}, "ISBN": ["9783805585248"], "references-count": 0, "URL": "http://dx.doi.org/10.1159/000139879"}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T23:17:30Z", "timestamp": 1574119050657}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1986, 6, 1]], "date-time": "1986-06-01T00:00:00Z", "timestamp": 517968000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer and Clinical Oncology"], "published-print": {"date-parts": [[1986, 6]]}, "DOI": "10.1016/0277-5379(86)90276-2", "type": "journal-article", "created": {"date-parts": [[2004, 4, 18]], "date-time": "2004-04-18T02:00:54Z", "timestamp": 1082253654000}, "page": "742", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Androgen levels in prostatic tissue of patients with carcinoma of the prostate treated with the combined therapy using an LHRH agonist and a pure antiandrogen"], "prefix": "10.1016", "volume": "22", "author": [{"given": "A.", "family": "B\u00e9langer", "sequence": "first", "affiliation": []}, {"given": "F.", "family": "Labrie", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Dupont", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer and Clinical Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:0277537986902762?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:0277537986902762?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 13]], "date-time": "2019-02-13T03:26:50Z", "timestamp": 1550028410000}, "score": 23.95551, "issued": {"date-parts": [[1986, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1986, 6]]}, "issue": "6"}, "alternative-id": ["0277537986902762"], "URL": "http://dx.doi.org/10.1016/0277-5379(86)90276-2", "ISSN": ["0277-5379"], "issn-type": [{"value": "0277-5379", "type": "print"}]}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T23:28:07Z", "timestamp": 1574810887937}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2007, 4, 1]]}, "DOI": "10.21236/ada469976", "type": "report", "created": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T16:12:19Z", "timestamp": 1500048739000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["New Approaches for Prostate Cancer Combination Therapy"], "prefix": "10.21236", "author": [{"given": "Luiz F.", "family": "Zerbini", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T16:12:20Z", "timestamp": 1500048740000}, "score": 23.221436, "subtitle": [""], "issued": {"date-parts": [[2007, 4, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada469976"}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T23:19:36Z", "timestamp": 1574810376433}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2008, 4, 1]]}, "DOI": "10.21236/ada482600", "type": "report", "created": {"date-parts": [[2017, 7, 13]], "date-time": "2017-07-13T21:14:38Z", "timestamp": 1499980478000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["New Approaches for Prostate Cancer Combination Therapy"], "prefix": "10.21236", "author": [{"given": "Luiz F.", "family": "Zerbini", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 7, 13]], "date-time": "2017-07-13T21:14:39Z", "timestamp": 1499980479000}, "score": 23.221436, "subtitle": [""], "issued": {"date-parts": [[2008, 4, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada482600"}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T23:28:58Z", "timestamp": 1574810938711}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2007, 1, 1]]}, "DOI": "10.21236/ada466559", "type": "report", "created": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T17:27:28Z", "timestamp": 1500053248000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Biological Impact of Senescence Induction in Prostate Cancer Therapy"], "prefix": "10.21236", "author": [{"given": "David F.", "family": "Jarrard", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T17:27:28Z", "timestamp": 1500053248000}, "score": 23.221436, "subtitle": [""], "issued": {"date-parts": [[2007, 1, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada466559"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T00:58:34Z", "timestamp": 1575161914471}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1996, 1, 1]], "date-time": "1996-01-01T00:00:00Z", "timestamp": 820454400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Radiotherapy and Oncology"], "published-print": {"date-parts": [[1996, 1]]}, "DOI": "10.1016/s0167-8140(96)80137-x", "type": "journal-article", "created": {"date-parts": [[2005, 7, 18]], "date-time": "2005-07-18T13:50:06Z", "timestamp": 1121694606000}, "page": "S35", "source": "Crossref", "is-referenced-by-count": 0, "title": ["128Beneficial effect of combination antiandrogen therapy administered prior and following external beam radiation therapy in localized prostate cancer"], "prefix": "10.1016", "volume": "40", "author": [{"given": "J.", "family": "Laverdi\u00e8re", "sequence": "first", "affiliation": []}, {"given": "J.L.", "family": "Gomez", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Cusan", "sequence": "additional", "affiliation": []}, {"given": "E.R.", "family": "Suburu", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Diamond", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Lemay", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Candas", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Labrie", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Radiotherapy and Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S016781409680137X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S016781409680137X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 24]], "date-time": "2019-01-24T12:51:24Z", "timestamp": 1548334284000}, "score": 23.087725, "issued": {"date-parts": [[1996, 1]]}, "references-count": 0, "alternative-id": ["S016781409680137X"], "URL": "http://dx.doi.org/10.1016/s0167-8140(96)80137-x", "ISSN": ["0167-8140"], "issn-type": [{"value": "0167-8140", "type": "print"}], "subject": ["Oncology", "Radiology Nuclear Medicine and imaging", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:38:21Z", "timestamp": 1574415501120}, "reference-count": 24, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 11, 1]], "date-time": "2011-11-01T00:00:00Z", "timestamp": 1320105600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Urology"], "published-print": {"date-parts": [[2011, 11]]}, "DOI": "10.1016/j.urology.2011.06.058", "type": "journal-article", "created": {"date-parts": [[2011, 11, 5]], "date-time": "2011-11-05T18:02:23Z", "timestamp": 1320516143000}, "page": "S494-S498", "source": "Crossref", "is-referenced-by-count": 6, "title": ["New Data, New Paradigms for Treating Prostate Cancer Patients\u2014VI: Novel Hormonal Therapy Approaches"], "prefix": "10.1016", "volume": "78", "author": [{"given": "Robert", "family": "Dreicer", "sequence": "first", "affiliation": []}, {"given": "Dean F.", "family": "Bajorin", "sequence": "additional", "affiliation": []}, {"given": "David G.", "family": "McLeod", "sequence": "additional", "affiliation": []}, {"given": "Daniel P.", "family": "Petrylak", "sequence": "additional", "affiliation": []}, {"given": "Judd W.", "family": "Moul", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Urology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0090429511024617?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0090429511024617?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 19]], "date-time": "2019-06-19T04:05:59Z", "timestamp": 1560917159000}, "score": 22.842123, "issued": {"date-parts": [[2011, 11]]}, "references-count": 24, "journal-issue": {"published-print": {"date-parts": [[2011, 11]]}, "issue": "5"}, "alternative-id": ["S0090429511024617"], "URL": "http://dx.doi.org/10.1016/j.urology.2011.06.058", "ISSN": ["0090-4295"], "issn-type": [{"value": "0090-4295", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T06:48:28Z", "timestamp": 1574750908739}, "publisher-location": "Cham", "reference-count": 39, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319499109", "type": "print"}, {"value": "9783319499116", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 1, 1]], "date-time": "2017-01-01T00:00:00Z", "timestamp": 1483228800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2017]]}, "DOI": "10.1007/978-3-319-49911-6_25", "type": "book-chapter", "created": {"date-parts": [[2017, 2, 22]], "date-time": "2017-02-22T05:52:44Z", "timestamp": 1487742764000}, "page": "325-343", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Transrectal Laser Focal Therapy of Prostate Cancer"], "prefix": "10.1007", "author": [{"given": "John F.", "family": "Feller", "sequence": "first", "affiliation": []}, {"given": "Bernadette M.", "family": "Greenwood", "sequence": "additional", "affiliation": []}, {"given": "R. Jason", "family": "Stafford", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 2, 23]]}, "reference": [{"key": "25_CR1", "unstructured": "Phase II Laser Focal Therapy of Prostate Cancer (LITT or FLA). NCT02243033. clinicaltrials.gov/ct2/show/NCT02243033. Accessed 14 Feb 2016."}, {"issue": "3", "key": "25_CR2", "doi-asserted-by": "crossref", "first-page": "932", "DOI": "10.1148/radiol.13121652", "volume": "267", "author": "A Oto", "year": "2013", "unstructured": "Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013;267(3):932\u201340.", "journal-title": "Radiology."}, {"issue": "4", "key": "25_CR3", "doi-asserted-by": "crossref", "first-page": "298", "DOI": "10.1002/lsm.21044", "volume": "43", "author": "O Garcia-Medina", "year": "2011", "unstructured": "Garcia-Medina O, Gorny K, McNichols R, Friese J, Misra S, Amrami K, et al. In vivo evaluation of a MR-guided 980 nm laser interstitial thermal therapy system for ablations in porcine liver. Lasers Surg Med. 2011;43(4):298\u2013305.", "journal-title": "Lasers Surg Med."}, {"issue": "4", "key": "25_CR4", "doi-asserted-by": "crossref", "first-page": "1514", "DOI": "10.1016/j.juro.2010.05.091", "volume": "184", "author": "RJ Stafford", "year": "2010", "unstructured": "Stafford RJ, Shetty A, Elliott AM, Klumpp SA, McNichols RJ, Gowda A, et al. Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol. 2010;184(4):1514\u201320.", "journal-title": "J Urol."}, {"key": "25_CR5", "unstructured": "Neff T. First-ever targeted laser prostate surgery a success. UCH Insider. 2009;3(8). http://www3.uch.edu/uchinsider/laser%20prostate%20surgery.pdf"}, {"key": "25_CR6", "unstructured": "MR-Guided Laser Ablation of Prostate Bed Recurrences. NCT01743638. https://clinicaltrials.gov/ct2/show/NCT01743638 . Accessed 15 Sept 2016."}, {"key": "25_CR7", "unstructured": "MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer. NCT00448695. https://clinicaltrials.gov/ct2/show/NCT00448695 . Accessed 15 Sept 2016."}, {"key": "25_CR8", "unstructured": "MR-Guided Laser Interstitial Thermal Therapy in Treating Patients with Prostate Cancer. NCT01792024. https://clinicaltrials.gov/ct2/show/NCT01792024 . Accessed 15 Sept 2016."}, {"issue": "1", "key": "25_CR9", "doi-asserted-by": "crossref", "first-page": "173", "DOI": "10.1016/j.eururo.2010.03.006", "volume": "58", "author": "O Raz", "year": "2010", "unstructured": "Raz O, Haider MA, Davidson SR, Lindner U, Hlasny E, Weersink R, et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol. 2010;58(1):173\u20137.", "journal-title": "Eur Urol."}, {"issue": "6", "key": "25_CR10", "doi-asserted-by": "crossref", "first-page": "1111", "DOI": "10.1016/j.eururo.2010.03.008", "volume": "57", "author": "U Lindner", "year": "2010", "unstructured": "Lindner U, Lawrentschuk N, Weersink RA, Davidson SR, Raz O, Hlasny E, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol. 2010;57(6):1111\u20134.", "journal-title": "Eur Urol."}, {"issue": "7", "key": "25_CR11", "doi-asserted-by": "crossref", "first-page": "929", "DOI": "10.1016/j.jvir.2011.02.039", "volume": "22", "author": "DA Woodrum", "year": "2011", "unstructured": "Woodrum DA, Mynderse LA, Gorny KR, Amrami KK, McNichols RJ, Callstrom MR. 3.0 T MR-guided laser ablation of a prostate cancer recurrence in the postsurgical prostate bed. J Vasc Interv Radiol. 2011;22(7):929\u201334.", "journal-title": "J Vasc Interv Radiol."}, {"issue": "3", "key": "25_CR12", "doi-asserted-by": "crossref", "first-page": "236", "DOI": "10.1097/MOU.0000000000000044", "volume": "24", "author": "H Wenger", "year": "2014", "unstructured": "Wenger H, Yousuf A, Oto A, Eggener S. Laser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014;24(3):236\u201340.", "journal-title": "Curr Opin Urol."}, {"issue": "4", "key": "25_CR13", "doi-asserted-by": "crossref", "first-page": "408", "DOI": "10.1016/j.yebeh.2012.04.135", "volume": "24", "author": "DJ Curry", "year": "2012", "unstructured": "Curry DJ, Gowda A, McNichols RJ, Wilfong AA. MR-guided stereotactic laser ablation of epileptogenic foci in children. Epilepsy Behav. 2012;24(4):408\u201314.", "journal-title": "Epilepsy Behav."}, {"issue": "5", "key": "25_CR14", "doi-asserted-by": "crossref", "first-page": "361", "DOI": "10.1002/lsm.22025", "volume": "44", "author": "A Carpentier", "year": "2012", "unstructured": "Carpentier A, Chauvet D, Reina V, Beccaria K, Leclerq D, McNichols RJ, et al. MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas. Lasers Surg Med. 2012;44(5):361\u20138.", "journal-title": "Lasers Surg Med."}, {"issue": "2", "key": "25_CR15", "doi-asserted-by": "crossref", "first-page": "576", "DOI": "10.1148/radiol.2342031887", "volume": "234", "author": "D Beyersdorff", "year": "2005", "unstructured": "Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology. 2005;234(2):576\u201381.", "journal-title": "Radiology."}, {"key": "25_CR16", "unstructured": "Schertz A. Advancements improve prostate exams. BizTimes. Aug 20, 2010."}, {"issue": "4", "key": "25_CR17", "doi-asserted-by": "crossref", "first-page": "771", "DOI": "10.1016/j.eururo.2014.09.018", "volume": "67", "author": "IA Donaldson", "year": "2015", "unstructured": "Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, et al. Focal therapy: patients, interventions, and outcomes\u2013a report from a consensus meeting. Eur Urol. 2015;67(4):771\u20137.", "journal-title": "Eur Urol."}, {"key": "25_CR18", "unstructured": "Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user\u2019s manual. Santa Monica, CA: RAND Corporation; 2001 . http://www.rand.org/pubs/monograph_reports/MR1269.html"}, {"issue": "7", "key": "25_CR19", "doi-asserted-by": "crossref", "first-page": "907", "DOI": "10.1007/s00345-015-1603-7", "volume": "33", "author": "H Poel van der", "year": "2015", "unstructured": "van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, et al. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol. 2015;33(7):907\u201316.", "journal-title": "World J Urol."}, {"key": "25_CR20", "unstructured": "Abd-Alazeez M, Ahmed HU, Arya M, Charman SC, Anastasiadis E, Freeman A, et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level\u2013can it rule out clinically significant prostate cancer? Urol Oncol. 2014;32(1):45.e17\u201322.", "DOI": "10.1016/j.urolonc.2013.06.007", "doi-asserted-by": "crossref"}, {"issue": "6", "key": "25_CR21", "doi-asserted-by": "crossref", "first-page": "1045", "DOI": "10.1016/j.eururo.2015.01.013", "volume": "68", "author": "JJ F\u00fctterer", "year": "2015", "unstructured": "F\u00fctterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045\u201353.", "journal-title": "Eur Urol."}, {"issue": "4", "key": "25_CR22", "doi-asserted-by": "crossref", "first-page": "234", "DOI": "10.4111/kju.2013.54.4.234", "volume": "54", "author": "K Shigemura", "year": "2013", "unstructured": "Shigemura K, Yamanaka N, Yamashita M. Can diffusion-weighted magnetic resonance imaging predict a high Gleason score of prostate cancer? Korean J Urol. 2013;54(4):234\u20138.", "journal-title": "Korean J Urol."}, {"key": "25_CR23", "doi-asserted-by": "crossref", "first-page": "374805", "DOI": "10.1155/2012/374805", "volume": "2012", "author": "R Nagarajan", "year": "2012", "unstructured": "Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol. 2012;2012:374805.", "journal-title": "Adv Urol."}, {"issue": "7", "key": "25_CR24", "doi-asserted-by": "crossref", "first-page": "774", "DOI": "10.1016/j.crad.2008.02.001", "volume": "63", "author": "NM deSouza", "year": "2008", "unstructured": "deSouza NM, Riches SF, Vanas NJ, Morgan VA, Ashley SA, Fisher C, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63(7):774\u201382.", "journal-title": "Clin Radiol."}, {"issue": "2", "key": "25_CR25", "doi-asserted-by": "crossref", "first-page": "453", "DOI": "10.1148/radiol.11091409", "volume": "259", "author": "T Hambrock", "year": "2011", "unstructured": "Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, van de Hulsbergen Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453\u201361.", "journal-title": "Radiology."}, {"issue": "1", "key": "25_CR26", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1016/j.eururo.2015.08.052", "volume": "69", "author": "JC Weinreb", "year": "2016", "unstructured": "Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging \u2013 reporting and data system: 2015, Version 2. Eur Urol. 2016;69(1):16\u201340.", "journal-title": "Eur Urol."}, {"key": "25_CR27", "unstructured": "Medtronic Indications, Safety, and Warnings Visualase Thermal Therapy System. http://www.medtronic.com/for-healthcare-professionals/products-therapies/neurological/laser-ablation/visualase/indications-safety-warnings/index.htm . Accessed 5 Mar 2016."}, {"key": "25_CR28", "unstructured": "U.S. Food and Drug Administration MAUDE Adverse Event Report Database. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=5101035 . Accessed 8 Mar 2016."}, {"issue": "2", "key": "25_CR29", "doi-asserted-by": "crossref", "first-page": "607", "DOI": "10.1016/S0022-5347(01)66464-4", "volume": "155", "author": "PA Nash", "year": "1996", "unstructured": "Nash PA, Bruce JE, Indudhara R, Shinohara K. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol. 1996;155(2):607\u20139.", "journal-title": "J Urol."}, {"key": "25_CR30", "unstructured": "Soloway MS, Obek C. Periprostatic local anesthesia before ultrasound guided prostate biopsy. J Urol. 2000163(1):172\u20133.", "DOI": "10.1016/S0022-5347(05)67997-9", "doi-asserted-by": "crossref"}, {"issue": "6b", "key": "25_CR31", "doi-asserted-by": "crossref", "first-page": "E105", "DOI": "10.1111/bju.12750", "volume": "114", "author": "J Le Nobin", "year": "2014", "unstructured": "Le Nobin J, Orczyk C, Deng FM, Melamed J, Rusinek H, Taneja SS, et al. Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software. BJU Int. 2014;114(6b):E105\u201312.", "journal-title": "BJU Int."}, {"key": "25_CR32", "unstructured": "Whinnery JR, Ausubel J, Langford HD; National Academy of Engineering. Lasers: invention to application. Washington, DC: National Academy Press; 1987."}, {"issue": "6", "key": "25_CR33", "doi-asserted-by": "crossref", "first-page": "814", "DOI": "10.1002/mrm.1910340606", "volume": "34", "author": "Y Ishihara", "year": "1995", "unstructured": "Ishihara Y, Calderon A, Watanabe H, Okamoto K, Suzuki Y, Kuroda K, et al. A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med. 1995;34(6):814\u201323.", "journal-title": "Magn Reson Med."}, {"issue": "2", "key": "25_CR34", "doi-asserted-by": "crossref", "first-page": "376", "DOI": "10.1002/jmri.21265", "volume": "27", "author": "V Rieke", "year": "2008", "unstructured": "Rieke V, Butts Pauly K. MR thermometry. J Magn Reson Imaging. 2008;27(2):376\u201390.", "journal-title": "J Magn Reson Imaging."}, {"key": "25_CR35", "first-page": "489", "volume": "43", "author": "FC Henriques", "year": "1947", "unstructured": "Henriques FC. Studies of thermal injury, V. The predictability and significance of thermally induced rate processes leading to irreversible epidermal injury. Arch Pathol. 1947;43:489\u2013502.", "journal-title": "Arch Pathol"}, {"issue": "4", "key": "25_CR36", "doi-asserted-by": "crossref", "first-page": "262", "DOI": "10.3109/02656736.2013.786140", "volume": "29", "author": "JA Pearce", "year": "2013", "unstructured": "Pearce JA. Comparative analysis of mathematical models of cell death and thermal damage processes. Int J Hyperthermia. 2013;29(4):262\u201380.", "journal-title": "Int J Hyperthermia."}, {"issue": "1", "key": "25_CR37", "doi-asserted-by": "crossref", "first-page": "48", "DOI": "10.1002/lsm.10243", "volume": "34", "author": "RJ McNichols", "year": "2004", "unstructured": "McNichols RJ, Gowda A, Kangasniemi M, Bankson JA, Price RE, Hazle JD. MR thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med. 2004;34(1):48\u201355.", "journal-title": "Lasers Surg Med."}, {"issue": "2", "key": "25_CR38", "first-page": "55", "volume": "16", "author": "T Lee", "year": "2014", "unstructured": "Lee T, Mendhiratta N, Sperling D, Lepor H. Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol. 2014;16(2):55\u201366.", "journal-title": "Rev Urol."}, {"issue": "6", "key": "25_CR39", "doi-asserted-by": "crossref", "first-page": "924", "DOI": "10.1016/j.eururo.2015.04.029", "volume": "68", "author": "H Lepor", "year": "2015", "unstructured": "Lepor H, Llukani E, Sperling D, F\u00fctterer JJ. Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. Eur Urol. 2015;68(6):924\u20136.", "journal-title": "Eur Urol."}], "container-title": ["Imaging and Focal Therapy of Early Prostate Cancer", "Current Clinical Urology"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-49911-6_25", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 18]], "date-time": "2019-09-18T23:32:22Z", "timestamp": 1568849542000}, "score": 22.348524, "issued": {"date-parts": [[2017]]}, "ISBN": ["9783319499109", "9783319499116"], "references-count": 39, "URL": "http://dx.doi.org/10.1007/978-3-319-49911-6_25", "relation": {"cites": []}, "ISSN": ["2197-7194", "2197-7208"], "issn-type": [{"value": "2197-7194", "type": "print"}, {"value": "2197-7208", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T20:20:25Z", "timestamp": 1574367625123}, "reference-count": 74, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Cancer Journal"], "published-print": {"date-parts": [[2007, 9]]}, "DOI": "10.1097/ppo.0b013e3181570121", "type": "journal-article", "created": {"date-parts": [[2008, 5, 4]], "date-time": "2008-05-04T11:34:57Z", "timestamp": 1209900897000}, "page": "318-326", "source": "Crossref", "is-referenced-by-count": 26, "title": ["Quality of Life After Therapy for Localized Prostate Cancer"], "prefix": "10.1097", "volume": "13", "author": [{"given": "David F.", "family": "Penson", "sequence": "first", "affiliation": []}], "member": "276", "container-title": ["The Cancer Journal"], "language": "en", "deposited": {"date-parts": [[2019, 2, 11]], "date-time": "2019-02-11T01:17:26Z", "timestamp": 1549847846000}, "score": 22.345459, "subtitle": [""], "issued": {"date-parts": [[2007, 9]]}, "references-count": 74, "journal-issue": {"issue": "5"}, "URL": "http://dx.doi.org/10.1097/ppo.0b013e3181570121", "ISSN": ["1528-9117"], "issn-type": [{"value": "1528-9117", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T17:01:24Z", "timestamp": 1574355684467}, "publisher-location": "Totowa, NJ", "reference-count": 128, "publisher": "Humana Press", "isbn-type": [{"value": "9781603274234", "type": "print"}, {"value": "9781603274241", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/978-1-60327-424-1_14", "type": "book-chapter", "created": {"date-parts": [[2008, 3, 6]], "date-time": "2008-03-06T16:11:35Z", "timestamp": 1204819895000}, "page": "289-304", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeted Therapy in Prostate Cancer"], "prefix": "10.1007", "author": [{"given": "Amado J.", "family": "Zurita", "sequence": "first", "affiliation": []}, {"given": "John F.", "family": "Ward", "sequence": "additional", "affiliation": []}, {"given": "Jeri", "family": "Kim", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"issue": "1", "key": "14_CR1", "doi-asserted-by": "publisher", "first-page": "34", "DOI": "10.1038/35094009", "volume": "1", "author": "BJ Feldman", "year": "2001", "unstructured": "Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34\u201345.", "journal-title": "Nat Rev Cancer"}, {"issue": "32", "key": "14_CR2", "doi-asserted-by": "publisher", "first-page": "8253", "DOI": "10.1200/JCO.2005.03.4777", "volume": "23", "author": "HI Scher", "year": "2005", "unstructured": "Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32):8253\u201361.", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "14_CR3", "doi-asserted-by": "publisher", "first-page": "8867", "DOI": "10.1158/0008-5472.CAN-04-2938", "volume": "64", "author": "R Berger", "year": "2004", "unstructured": "Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004;64(24):8867\u201375.", "journal-title": "Cancer Res"}, {"issue": "7", "key": "14_CR4", "doi-asserted-by": "publisher", "first-page": "2972", "DOI": "10.1210/jc.2002-022038", "volume": "88", "author": "IV Litvinov", "year": "2003", "unstructured": "Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles\u2019 heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88(7):2972\u201382.", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "22", "key": "14_CR5", "doi-asserted-by": "publisher", "first-page": "1687", "DOI": "10.1093/jnci/93.22.1687", "volume": "93", "author": "ME Grossmann", "year": "2001", "unstructured": "Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93(22):1687\u201397.", "journal-title": "J Natl Cancer Inst"}, {"issue": "1", "key": "14_CR6", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1038/nm972", "volume": "10", "author": "CD Chen", "year": "2004", "unstructured": "Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33\u20139.", "journal-title": "Nat Med"}, {"issue": "4", "key": "14_CR7", "doi-asserted-by": "publisher", "first-page": "1151", "DOI": "10.1073/pnas.0408925102", "volume": "102", "author": "G Han", "year": "2005", "unstructured": "Han G, Buchanan G, Ittmann M, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 2005;102(4):1151\u20136.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "4", "key": "14_CR8", "first-page": "1008", "volume": "62", "author": "OL Zegarra-Moro", "year": "2002", "unstructured": "Zegarra-Moro OL, Schmidt LJ, Huang H, et al. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62(4):1008\u201313.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "14_CR9", "doi-asserted-by": "crossref", "first-page": "217", "DOI": "10.1016/S0002-9440(10)63112-4", "volume": "164", "author": "J Holzbeierlein", "year": "2004", "unstructured": "Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164(1):217\u201327.", "journal-title": "Am J Pathol"}, {"issue": "46", "key": "14_CR10", "doi-asserted-by": "publisher", "first-page": "6718", "DOI": "10.1038/sj.onc.1204889", "volume": "20", "author": "S Mousses", "year": "2001", "unstructured": "Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20(46):6718\u201323.", "journal-title": "Oncogene"}, {"issue": "24", "key": "14_CR11", "doi-asserted-by": "publisher", "first-page": "9209", "DOI": "10.1158/0008-5472.CAN-04-2442", "volume": "64", "author": "RB Shah", "year": "2004", "unstructured": "Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64(24):9209\u201316.", "journal-title": "Cancer Res"}, {"issue": "3", "key": "14_CR12", "doi-asserted-by": "publisher", "first-page": "552", "DOI": "10.1038/sj.bjc.6601127", "volume": "89", "author": "J Edwards", "year": "2003", "unstructured": "Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552\u20136.", "journal-title": "Br J Cancer"}, {"issue": "7", "key": "14_CR13", "first-page": "2892", "volume": "61", "author": "CW Gregory", "year": "2001", "unstructured": "Gregory CW, Johnson RT Jr, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61(7):2892\u20138.", "journal-title": "Cancer Res"}, {"issue": "9", "key": "14_CR14", "first-page": "3550", "volume": "61", "author": "MJ Linja", "year": "2001", "unstructured": "Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550\u20135.", "journal-title": "Cancer Res"}, {"issue": "43", "key": "14_CR15", "doi-asserted-by": "publisher", "first-page": "15969", "DOI": "10.1073/pnas.0604193103", "volume": "103", "author": "S Chen", "year": "2006", "unstructured": "Chen S, Xu Y, Yuan X, et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A 2006;103(43):15969\u201374.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "4", "key": "14_CR16", "doi-asserted-by": "publisher", "first-page": "293", "DOI": "10.1042/CS20040329", "volume": "108", "author": "D. Gioeli", "year": "2005", "unstructured": "Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108(4):293\u2013308.", "journal-title": "Clin Sci (Lond)"}, {"issue": "2", "key": "14_CR17", "doi-asserted-by": "publisher", "first-page": "362", "DOI": "10.1002/jcb.20811", "volume": "99", "author": "IU Agoulnik", "year": "2006", "unstructured": "Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006;99(2):362\u201372.", "journal-title": "J Cell Biochem"}, {"issue": "13", "key": "14_CR18", "doi-asserted-by": "publisher", "first-page": "3001", "DOI": "10.1200/JCO.2002.10.018", "volume": "20", "author": "EP. Gelmann", "year": "2002", "unstructured": "Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13):3001\u201315.", "journal-title": "J Clin Oncol"}, {"issue": "19", "key": "14_CR19", "doi-asserted-by": "publisher", "first-page": "7331", "DOI": "10.1128/MCB.00581-06", "volume": "26", "author": "Li Jia", "year": "2006", "unstructured": "Jia Li, Shen HC, Wantroba M, et al. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 2006;26(19):7331\u201341.", "journal-title": "Mol Cell Biol"}, {"issue": "2", "key": "14_CR20", "doi-asserted-by": "publisher", "first-page": "440", "DOI": "10.1158/1078-0432.CCR-1146-03", "volume": "10", "author": "JL Mohler", "year": "2004", "unstructured": "Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440\u20138.", "journal-title": "Clin Cancer Res"}, {"issue": "13", "key": "14_CR21", "doi-asserted-by": "publisher", "first-page": "4653", "DOI": "10.1158/1078-0432.CCR-05-0525", "volume": "11", "author": "MA Titus", "year": "2005", "unstructured": "Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11(13):4653\u20137.", "journal-title": "Clin Cancer Res"}, {"issue": "5", "key": "14_CR22", "doi-asserted-by": "publisher", "first-page": "2815", "DOI": "10.1158/0008-5472.CAN-05-4000", "volume": "66", "author": "M Stanbrough", "year": "2006", "unstructured": "Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815\u201325.", "journal-title": "Cancer Res"}, {"issue": "14", "key": "14_CR23", "doi-asserted-by": "publisher", "first-page": "1623", "DOI": "10.2174/0929867054367185", "volume": "12", "author": "F. Leroux", "year": "2005", "unstructured": "Leroux F. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer. Curr Med Chem 2005;12(14):1623\u20139.", "journal-title": "Curr Med Chem"}, {"key": "14_CR24", "unstructured": "Attard G, Yap TA, Reid AH, et al. Activity, toxicity, and effect on steroid precursor levels of abiraterone (A), an oral irreversible inhibitor of CYP17 (17\u03b1 hydroxylase/17,20 lyase), in castrate men with castration refractory prostate cancer (CRPC). Presented at the Prostate Cancer Symposium, 2007. Abstract 264."}, {"issue": "17", "key": "14_CR25", "doi-asserted-by": "publisher", "first-page": "6201", "DOI": "10.1073/pnas.0500381102", "volume": "102", "author": "CE Bohl", "year": "2005", "unstructured": "Bohl CE, Gao W, Miller DD, et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 2005;102(17):6201\u20136.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "9", "key": "14_CR26", "doi-asserted-by": "publisher", "first-page": "4904", "DOI": "10.1073/pnas.081565498", "volume": "98", "author": "JS Sack", "year": "2001", "unstructured": "Sack JS, Kish KF, Wang C, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001;98(9):4904\u20139.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "14_CR27", "doi-asserted-by": "publisher", "first-page": "13648", "DOI": "10.1074/jbc.M611711200", "volume": "282", "author": "CE Bohl", "year": "2007", "unstructured": "Bohl CE, Wu Z, Miller DD, et al. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 2007;282:13648\u201355.", "journal-title": "J Biol Chem"}, {"issue": "5", "key": "14_CR28", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1016/S0093-7754(03)00346-4", "volume": "30", "author": "DB Solit", "year": "2003", "unstructured": "Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003;30(5):709\u201316.", "journal-title": "Semin Oncol"}, {"issue": "18", "key": "14_CR29", "doi-asserted-by": "publisher", "first-page": "4152", "DOI": "10.1200/JCO.2005.00.612", "volume": "23", "author": "U Banerji", "year": "2005", "unstructured": "Banerji U, O\u2019Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23(18):4152\u201361.", "journal-title": "J Clin Oncol"}, {"issue": "6", "key": "14_CR30", "doi-asserted-by": "publisher", "first-page": "1078", "DOI": "10.1200/JCO.2005.09.119", "volume": "23", "author": "MP Goetz", "year": "2005", "unstructured": "Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23(6):1078\u201387.", "journal-title": "J Clin Oncol"}, {"issue": "9", "key": "14_CR31", "doi-asserted-by": "publisher", "first-page": "1885", "DOI": "10.1200/JCO.2005.12.085", "volume": "23", "author": "JL Grem", "year": "2005", "unstructured": "Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23(9):1885\u201393.", "journal-title": "J Clin Oncol"}, {"issue": "18", "key": "14_CR32", "first-page": "5165", "volume": "60", "author": "LM Butler", "year": "2000", "unstructured": "Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60(18):5165\u201370.", "journal-title": "Cancer Res"}, {"issue": "9", "key": "14_CR33", "doi-asserted-by": "publisher", "first-page": "1311", "DOI": "10.1158/1535-7163.MCT-04-0287", "volume": "4", "author": "L Chen", "year": "2005", "unstructured": "Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4(9):1311\u20139.", "journal-title": "Mol Cancer Ther"}, {"issue": "1", "key": "14_CR34", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1016/j.molcel.2006.12.008", "volume": "25", "author": "BT Scroggins", "year": "2007", "unstructured": "Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007;25(1):151\u20139.", "journal-title": "Mol Cell"}, {"issue": "7046", "key": "14_CR35", "doi-asserted-by": "publisher", "first-page": "1262", "DOI": "10.1038/nature03672", "volume": "435", "author": "DB Seligson", "year": "2005", "unstructured": "Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262\u20136.", "journal-title": "Nature"}, {"issue": "2", "key": "14_CR36", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1093/jnci/dji010", "volume": "97", "author": "LC Li", "year": "2005", "unstructured": "Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005;97(2):103\u201315.", "journal-title": "J Natl Cancer Inst"}, {"key": "14_CR37", "first-page": "14554", "volume": "24(i>18S", "author": "R Molife", "year": "2006", "unstructured": "Molife R, Patterson S, Riggs C, et al. Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC). J Clin Oncol 2006;24(i>18S):14554.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "14_CR38", "doi-asserted-by": "publisher", "first-page": "979", "DOI": "10.1677/erc.1.01115", "volume": "13", "author": "CJ Burd", "year": "2006", "unstructured": "Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 2006;13(4):979\u201394.", "journal-title": "Endocr Relat Cancer"}, {"issue": "11", "key": "14_CR39", "doi-asserted-by": "publisher", "first-page": "919", "DOI": "10.1007/s00109-006-0081-1", "volume": "84", "author": "JH Bebermeier", "year": "2006", "unstructured": "Bebermeier JH, Brooks JD, Deprimo SE, et al. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. J Mol Med 2006;84(11):919\u201331.", "journal-title": "J Mol Med"}, {"issue": "11", "key": "14_CR40", "doi-asserted-by": "publisher", "first-page": "2633", "DOI": "10.1210/me.2004-0245", "volume": "18", "author": "Z Kang", "year": "2004", "unstructured": "Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18(11):2633\u201348.", "journal-title": "Mol Endocrinol"}, {"issue": "22", "key": "14_CR41", "doi-asserted-by": "publisher", "first-page": "11039", "DOI": "10.1158/0008-5472.CAN-06-2442", "volume": "66", "author": "J Yan", "year": "2006", "unstructured": "Yan J, Yu CT, Ozen M, et al. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 2006;66(22):11039\u201346.", "journal-title": "Cancer Res"}, {"issue": "20", "key": "14_CR42", "first-page": "5632", "volume": "62", "author": "JD Debes", "year": "2002", "unstructured": "Debes JD, Schmidt LJ, Huang H, et al. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62(20):5632\u20136.", "journal-title": "Cancer Res"}, {"issue": "24", "key": "14_CR43", "first-page": "5718", "volume": "58", "author": "CW Gregory", "year": "1998", "unstructured": "Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58(24):5718\u201324.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "14_CR44", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1002/cncr.20327", "volume": "101", "author": "H Hong", "year": "2004", "unstructured": "Hong H, Kao C, Jeng MH, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004;101(1):83\u20139.", "journal-title": "Cancer"}, {"key": "14_CR45", "doi-asserted-by": "publisher", "first-page": "6511", "DOI": "10.1074/jbc.M408972200", "volume": "280", "author": "MC Hodgson", "year": "2005", "unstructured": "Hodgson MC, Astapova I, Cheng S, et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005;280:6511\u20139.", "journal-title": "J Biol Chem"}, {"issue": "3", "key": "14_CR46", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1038/sj.onc.1209020", "volume": "25", "author": "DJ Mulholland", "year": "2006", "unstructured": "Mulholland DJ, Dedhar S, Wu H, et al. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006;25(3):329\u201337.", "journal-title": "Oncogene"}, {"issue": "7", "key": "14_CR47", "doi-asserted-by": "publisher", "first-page": "489", "DOI": "10.1038/nrc839", "volume": "2", "author": "I Vivanco", "year": "2002", "unstructured": "Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489\u2013501.", "journal-title": "Nat Rev Cancer"}, {"issue": "15", "key": "14_CR48", "doi-asserted-by": "publisher", "first-page": "5232", "DOI": "10.1158/0008-5472.CAN-04-0272", "volume": "64", "author": "JI Kreisberg", "year": "2004", "unstructured": "Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64(15):5232\u20136.", "journal-title": "Cancer Res"}, {"issue": "19", "key": "14_CR49", "doi-asserted-by": "publisher", "first-page": "6572", "DOI": "10.1158/1078-0432.CCR-04-0477", "volume": "10", "author": "G Ayala", "year": "2004", "unstructured": "Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10(19):6572\u20138.", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "14_CR50", "doi-asserted-by": "publisher", "first-page": "572", "DOI": "10.1093/carcin/bgl193", "volume": "28", "author": "B Li", "year": "2007", "unstructured": "Li B, Sun A, Youn H, et al. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 2007;28(3):572\u201383.", "journal-title": "Carcinogenesis"}, {"issue": "3", "key": "14_CR51", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1016/j.ccr.2006.02.027", "volume": "9", "author": "JB Easton", "year": "2006", "unstructured": "Easton JB, Kurmasheva RT, Houghton PJ. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 2006;9(3):153\u20135.", "journal-title": "Cancer Cell"}, {"issue": "2", "key": "14_CR52", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.1097/00001813-200302000-00011", "volume": "14", "author": "GA Ruiter", "year": "2003", "unstructured": "Ruiter GA, Zerp SF, Bartelink H, et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003;14(2):167\u201373.", "journal-title": "Anticancer Drugs"}, {"issue": "11", "key": "14_CR53", "first-page": "1093", "volume": "2", "author": "SB Kondapaka", "year": "2003", "unstructured": "Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093\u2013103.", "journal-title": "Mol Cancer Ther"}, {"issue": "16S", "key": "14_CR54", "doi-asserted-by": "crossref", "first-page": "4642", "DOI": "10.1200/jco.2005.23.16_suppl.4642", "volume": "23", "author": "KG Chee", "year": "2005", "unstructured": "Chee KG, Lara PN, Longmate J, et al. The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): a phase II California Cancer Consortium Trial. J Clin Oncol 2005;23(16S):4642.", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "14_CR55", "doi-asserted-by": "crossref", "first-page": "1133", "DOI": "10.4161/cbt.4.10.2064", "volume": "4", "author": "EM Posadas", "year": "2005", "unstructured": "Posadas EM, Gulley J, Arlen PM, et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005;4(10):1133\u20137.", "journal-title": "Cancer Biol Ther"}, {"issue": "3", "key": "14_CR56", "doi-asserted-by": "publisher", "first-page": "280", "DOI": "10.1038/6495", "volume": "5", "author": "N Craft", "year": "1999", "unstructured": "Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5(3):280\u20135.", "journal-title": "Nat Med"}, {"issue": "20", "key": "14_CR57", "first-page": "5474", "volume": "54", "author": "Z Culig", "year": "1994", "unstructured": "Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54(20):5474\u20138.", "journal-title": "Cancer Res"}, {"issue": "8", "key": "14_CR58", "doi-asserted-by": "publisher", "first-page": "7119", "DOI": "10.1074/jbc.M307649200", "volume": "279", "author": "CW Gregory", "year": "2004", "unstructured": "Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279(8):7119\u201330.", "journal-title": "J Biol Chem"}, {"issue": "10", "key": "14_CR59", "doi-asserted-by": "publisher", "first-page": "7329", "DOI": "10.1074/jbc.M610447200", "volume": "282", "author": "W Fan", "year": "2007", "unstructured": "Fan W, Yanase T, Morinaga H, et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007;282(10):7329\u201338.", "journal-title": "J Biol Chem"}, {"issue": "16", "key": "14_CR60", "first-page": "6276", "volume": "61", "author": "T Nickerson", "year": "2001", "unstructured": "Nickerson T, Chang F, Lorimer D, et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61(16):6276\u201380.", "journal-title": "Cancer Res"}, {"issue": "11", "key": "14_CR61", "first-page": "3058", "volume": "60", "author": "H Miyake", "year": "2000", "unstructured": "Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000;60(11):3058\u201364.", "journal-title": "Cancer Res"}, {"issue": "13", "key": "14_CR62", "first-page": "3575", "volume": "63", "author": "S Kiyama", "year": "2003", "unstructured": "Kiyama S, Morrison K, Zellweger T, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63(13):3575\u201384.", "journal-title": "Cancer Res"}, {"issue": "13", "key": "14_CR63", "doi-asserted-by": "publisher", "first-page": "5563", "DOI": "10.1073/pnas.0609139104", "volume": "104", "author": "R Mehrian-Shai", "year": "2007", "unstructured": "Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007;104(13):5563\u20138.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "14_CR64", "first-page": "311a", "volume": "16", "author": "SF Slovin", "year": "1997", "unstructured": "Slovin SF, Kelly WK, Cohen R, et al. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): results of a phase Ib/IIa study. Proc Am Soc Clin Oncol 1997;16:311a.", "journal-title": "Proc Am Soc Clin Oncol"}, {"issue": "4", "key": "14_CR65", "doi-asserted-by": "publisher", "first-page": "332", "DOI": "10.1002/pros.20065", "volume": "60", "author": "A Ziada", "year": "2004", "unstructured": "Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004;60(4):332\u20137.", "journal-title": "Prostate"}, {"issue": "10", "key": "14_CR66", "doi-asserted-by": "publisher", "first-page": "2125", "DOI": "10.1002/cncr.20228", "volume": "100", "author": "PN Lara Jr", "year": "2004", "unstructured": "Lara PN Jr, Chee KG, Longmate J, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004;100(10):2125\u201331.", "journal-title": "Cancer"}, {"issue": "4", "key": "14_CR67", "doi-asserted-by": "publisher", "first-page": "980", "DOI": "10.1002/cncr.10339", "volume": "94", "author": "MJ Morris", "year": "2002", "unstructured": "Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94(4):980\u20136.", "journal-title": "Cancer"}, {"issue": "3", "key": "14_CR68", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1200/JCO.2006.07.0888", "volume": "25", "author": "JS Bono De", "year": "2007", "unstructured": "De Bono JS, Bellmunt J, Attard G, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007;25(3):257\u201362.", "journal-title": "J Clin Oncol"}, {"issue": "6", "key": "14_CR69", "doi-asserted-by": "publisher", "first-page": "675", "DOI": "10.1200/JCO.2006.07.0649", "volume": "25", "author": "DB Agus", "year": "2007", "unstructured": "Agus DB, Sweeney CJ, Morris MJ, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007;25(6):675\u201381.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "14_CR70", "doi-asserted-by": "publisher", "first-page": "455", "DOI": "10.1200/JCO.2005.02.129", "volume": "23", "author": "CM Canil", "year": "2005", "unstructured": "Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23(3):455\u201360.", "journal-title": "J Clin Oncol"}, {"key": "14_CR71", "unstructured": "Gravis G, Goncalves A, Bladou F, et al. A phase II study of erlotinib in advanced prostate cancer. Presented at the Prostate Cancer Symposium, 2006. Abstract 245."}, {"key": "14_CR72", "unstructured": "Nabhan C, Tolzien K, Newman S, et al. Phase II trial investigating the efficacy and toxicity of single agent erlotinib in chemotherapy-na\u00efve androgen-independent metastatic prostate cancer. Presented at the Prostate Cancer Symposium, 2007. Abstract 240."}, {"key": "14_CR73", "unstructured": "Sridhar SS, Hotte SJ, Chin JL, et al. A multicenter phase II study of lapatinib in hormone sensitive prostate cancer (HSPC). Presente at the Prostate Cancer Symposium, 2007. Abstract 261."}, {"issue": "3", "key": "14_CR74", "doi-asserted-by": "publisher", "first-page": "241", "DOI": "10.1200/JCO.2006.08.8187", "volume": "25", "author": "DB Solit", "year": "2007", "unstructured": "Solit DB, Rosen N. Targeting HER2 in prostate cancer: where to next? J Clin Oncol 2007;25(3):241\u20133.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "14_CR75", "doi-asserted-by": "publisher", "first-page": "82", "DOI": "10.1038/ncpuro0700", "volume": "4", "author": "EC Nelson", "year": "2007", "unstructured": "Nelson EC, Cambio AJ, Yang JC, et al. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nat Clin Pract Urol 2007;4(2):82\u201394.", "journal-title": "Nat Clin Pract Urol"}, {"issue": "4", "key": "14_CR76", "doi-asserted-by": "publisher", "first-page": "309", "DOI": "10.1016/j.ccr.2006.08.021", "volume": "10", "author": "Z Guo", "year": "2006", "unstructured": "Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10(4):309\u201319.", "journal-title": "Cancer Cell"}, {"issue": "24", "key": "14_CR77", "first-page": "6940", "volume": "52", "author": "TJ McDonnell", "year": "1992", "unstructured": "McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940\u20134.", "journal-title": "Cancer Res"}, {"issue": "6", "key": "14_CR78", "doi-asserted-by": "publisher", "first-page": "594", "DOI": "10.1038/nm1052", "volume": "10", "author": "PK Majumder", "year": "2004", "unstructured": "Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10(6):594\u2013601.", "journal-title": "Nat Med"}, {"issue": "10", "key": "14_CR79", "doi-asserted-by": "publisher", "first-page": "3854", "DOI": "10.1158/1078-0432.CCR-04-2145", "volume": "11", "author": "AW Tolcher", "year": "2005", "unstructured": "Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11(10):3854\u201361.", "journal-title": "Clin Cancer Res"}, {"key": "14_CR80", "unstructured": "Sternberg CN, Dumez H, Van Poppel H, et al. Multicenter randomized EORTC trial 30021 of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC). Presented at the Prostate Cancer Symposium, 2007. Abstract 144."}, {"issue": "1", "key": "14_CR81", "doi-asserted-by": "publisher", "first-page": "34", "DOI": "10.1093/jnci/92.1.34", "volume": "92", "author": "H Miayake", "year": "2000", "unstructured": "Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000;92(1):34\u201341.", "journal-title": "J Natl Cancer Inst"}, {"issue": "9", "key": "14_CR82", "doi-asserted-by": "publisher", "first-page": "909", "DOI": "10.1038/ncb1291", "volume": "7", "author": "H Zhang", "year": "2005", "unstructured": "Zhang H, Kim JK, Edwards CA, et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7(9):909\u201315.", "journal-title": "Nat Cell Biol"}, {"issue": "9", "key": "14_CR83", "first-page": "2547", "volume": "60", "author": "H Miyake", "year": "2000", "unstructured": "Miyake H, Nelson C, Rennie PS, et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60(9):2547\u201354.", "journal-title": "Cancer Res"}, {"issue": "17", "key": "14_CR84", "doi-asserted-by": "crossref", "first-page": "1287", "DOI": "10.1093/jnci/dji252", "volume": "97", "author": "KN Chi", "year": "2005", "unstructured": "Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u2019-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97(17):1287\u201396.", "journal-title": "J Natl Cancer Inst"}, {"issue": "15", "key": "14_CR85", "doi-asserted-by": "publisher", "first-page": "2474", "DOI": "10.1038/sj.onc.1208490", "volume": "24", "author": "M Zhang", "year": "2005", "unstructured": "Zhang M, Latham DE, Delaney MA, et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24(15):2474\u201382.", "journal-title": "Oncogene"}, {"key": "14_CR86", "unstructured": "Tolcher AW, Karavasilis V, Hudes G, et al. YM155, a novel survivin suppressant, demonstrates activity in subjects with hormone refractory prostate cancer (HRPC) previously treated with taxane chemotherapy. Presented at the International Symposium on Targeted Anticancer Therapies, 2007. Abstract 404."}, {"issue": "3", "key": "14_CR87", "doi-asserted-by": "publisher", "first-page": "994", "DOI": "10.1158/0008-5472.CAN-03-1382", "volume": "64", "author": "J Dai", "year": "2004", "unstructured": "Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64(3):994\u20139.", "journal-title": "Cancer Res"}, {"issue": "11", "key": "14_CR88", "doi-asserted-by": "publisher", "first-page": "783", "DOI": "10.1093/jnci/djj211", "volume": "98", "author": "SJ Kim", "year": "2006", "unstructured": "Kim SJ, Uehara H, Yazici S, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006;98(11):783\u201393.", "journal-title": "J Natl Cancer Inst"}, {"key": "14_CR89", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1046/j.1525-1411.2001.32007.x", "volume": "3", "author": "DM Reese", "year": "2001", "unstructured": "Reese DM, Fratesi P, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001;3:65\u201370.", "journal-title": "Prostate J"}, {"key": "14_CR90", "unstructured": "Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22. Abstract 1578."}, {"issue": "1", "key": "14_CR91", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1002/cncr.21956", "volume": "107", "author": "BI Rini", "year": "2006", "unstructured": "Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107(1):67\u201374.", "journal-title": "Cancer"}, {"issue": "4", "key": "14_CR92", "doi-asserted-by": "publisher", "first-page": "1224", "DOI": "10.1158/1078-0432.CCR-06-1938", "volume": "13", "author": "E Efstathiou", "year": "2007", "unstructured": "Efstathiou E, Troncoso P, Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007;13(4):1224\u201331.", "journal-title": "Clin Cancer Res"}, {"issue": "7", "key": "14_CR93", "first-page": "1888", "volume": "7", "author": "WD Figg", "year": "2001", "unstructured": "Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7(7):1888\u201393.", "journal-title": "Clin Cancer Res"}, {"issue": "6", "key": "14_CR94", "doi-asserted-by": "publisher", "first-page": "822", "DOI": "10.1038/sj.bjc.6600817", "volume": "88", "author": "MJ Drake", "year": "2003", "unstructured": "Drake MJ, Robson W, Mehta P, et al. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88(6):822\u20137.", "journal-title": "Br J Cancer"}, {"issue": "13", "key": "14_CR95", "doi-asserted-by": "publisher", "first-page": "2532", "DOI": "10.1200/JCO.2004.05.074", "volume": "22", "author": "WL Dahut", "year": "2004", "unstructured": "Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532\u20139.", "journal-title": "J Clin Oncol"}, {"key": "14_CR96", "unstructured": "Ning YM, Gulley J, Arlen P, et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Presented at the Prostate Cancer Symposium, 2007. Abstract 228."}, {"issue": "16", "key": "14_CR97", "doi-asserted-by": "publisher", "first-page": "3323", "DOI": "10.1200/JCO.2004.10.116", "volume": "22", "author": "P Mathew", "year": "2004", "unstructured": "Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22(16):3323\u20139.", "journal-title": "J Clin Oncol"}, {"key": "14_CR98", "first-page": "4506", "volume": "24", "author": "WL Dahut", "year": "2006", "unstructured": "Dahut WL, Scripture CD, Posadas EM, et al. Bony metastatic disease responses to sorafenib (BAY 43\u20139006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol 2006;24:4506.", "journal-title": "J Clin Oncol"}, {"key": "14_CR99", "first-page": "4562", "volume": "24", "author": "P Mathew", "year": "2006", "unstructured": "Mathew P, Thall PF, Johnson MM, et al. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). J Clin Oncol 2006;24:4562.", "journal-title": "J Clin Oncol"}, {"issue": "suppl", "key": "14_CR100", "doi-asserted-by": "publisher", "first-page": "758", "DOI": "10.1002/cncr.11151", "volume": "97", "author": "HI. Scher", "year": "2003", "unstructured": "Scher HI. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer 2003;97(suppl):758\u201371.", "journal-title": "Cancer"}, {"issue": "5", "key": "14_CR101", "doi-asserted-by": "publisher", "first-page": "783", "DOI": "10.1002/ijc.20314", "volume": "111", "author": "K Jung", "year": "2004", "unstructured": "Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111(5):783\u201391.", "journal-title": "Int J Cancer"}, {"issue": "9", "key": "14_CR102", "doi-asserted-by": "publisher", "first-page": "944", "DOI": "10.1038/nm0995-944", "volume": "1", "author": "JB Nelson", "year": "1995", "unstructured": "Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944\u20139.", "journal-title": "Nat Med"}, {"issue": "19", "key": "14_CR103", "doi-asserted-by": "publisher", "first-page": "10954", "DOI": "10.1073/pnas.1830978100", "volume": "100", "author": "JJ Yin", "year": "2003", "unstructured": "Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100(19):10954\u20139.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "3", "key": "14_CR104", "doi-asserted-by": "publisher", "first-page": "1143", "DOI": "10.1097/01.ju.0000042162.08938.27", "volume": "169", "author": "JB Nelson", "year": "2003", "unstructured": "Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169(3):1143\u20139.", "journal-title": "J Urol"}, {"issue": "4", "key": "14_CR105", "doi-asserted-by": "publisher", "first-page": "679", "DOI": "10.1200/JCO.2003.04.176", "volume": "21", "author": "MA Carducci", "year": "2003", "unstructured": "Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679\u201389.", "journal-title": "J Clin Oncol"}, {"issue": "14S", "key": "14_CR106", "doi-asserted-by": "crossref", "first-page": "4508", "DOI": "10.1200/jco.2004.22.14_suppl.4508", "volume": "22", "author": "M Carducci", "year": "2004", "unstructured": "Carducci M, Nelson JB, Saad F, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol 2004;22(14S):4508.", "journal-title": "J Clin Oncol"}, {"issue": "18S", "key": "14_CR107", "first-page": "4630", "volume": "24", "author": "DJ Sleep", "year": "2006", "unstructured": "Sleep DJ, Nelson JB, Petrylak DP, et al. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. J Clin Oncol 2006;24(18S):4630.", "journal-title": "J Clin Oncol"}, {"key": "14_CR108", "unstructured": "Nelson JB, Chin JL, Love W, et al. Results of a phase 3 randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). Presented at the Prostate Cancer Symposium, 2007. Abstract 146.", "DOI": "10.1002/cncr.23864", "doi-asserted-by": "crossref"}, {"issue": "6937", "key": "14_CR109", "doi-asserted-by": "publisher", "first-page": "337", "DOI": "10.1038/nature01658", "volume": "423", "author": "WJ Boyle", "year": "2003", "unstructured": "Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423(6937):337\u201342.", "journal-title": "Nature"}, {"key": "14_CR110", "unstructured": "Fizazi K, Bosserman L, Lipton A, et al. Phase II randomized trial of denosumab in patients with bone metastases from prostate cancer and elevated urine N- telopeptide levels after receiving zoledronic acid. Presented at the Prostate Cancer Symposium, 2007. Abstract 272."}, {"issue": "2", "key": "14_CR111", "doi-asserted-by": "publisher", "first-page": "165", "DOI": "10.1016/S0012-1606(02)00031-3", "volume": "253", "author": "PC Marker", "year": "2003", "unstructured": "Marker PC, Donjacour AA, Dahiya R, et al. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003;253(2):165\u201374.", "journal-title": "Dev Biol"}, {"issue": "25", "key": "14_CR112", "doi-asserted-by": "publisher", "first-page": "14565", "DOI": "10.1073/pnas.251140998", "volume": "98", "author": "M Mercader", "year": "2001", "unstructured": "Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98(25):14565\u201370.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "6", "key": "14_CR113", "doi-asserted-by": "publisher", "first-page": "893", "DOI": "10.1016/S0090-4295(97)00456-1", "volume": "50", "author": "RB Alexander", "year": "1997", "unstructured": "Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 1997;50(6):893\u20139.", "journal-title": "Urology"}, {"issue": "1", "key": "14_CR114", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1002/1097-0045(20000615)44:1<49::AID-PROS7>3.0.CO;2-7", "volume": "44", "author": "S Ponniah", "year": "2000", "unstructured": "Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000;44(1):49\u201354.", "journal-title": "Prostate"}, {"issue": "20", "key": "14_CR115", "first-page": "5160", "volume": "59", "author": "JW Simons", "year": "1999", "unstructured": "Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59(20):5160\u20138.", "journal-title": "Cancer Res"}, {"issue": "9", "key": "14_CR116", "first-page": "2444", "volume": "60", "author": "AA Hurwitz", "year": "2000", "unstructured": "Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444\u20138.", "journal-title": "Cancer Res"}, {"issue": "26", "key": "14_CR117", "doi-asserted-by": "publisher", "first-page": "15074", "DOI": "10.1073/pnas.96.26.15074", "volume": "96", "author": "ED Kwon", "year": "1999", "unstructured": "Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999;96(26):15074\u20139.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "15", "key": "14_CR118", "doi-asserted-by": "publisher", "first-page": "8099", "DOI": "10.1073/pnas.94.15.8099", "volume": "94", "author": "ED Kwon", "year": "1997", "unstructured": "Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997;94(15):8099\u2013103.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "7", "key": "14_CR119", "first-page": "3113", "volume": "159", "author": "L Fong", "year": "1997", "unstructured": "Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997;159(7):3113\u20137.", "journal-title": "J Immunol"}, {"issue": "7", "key": "14_CR120", "first-page": "1760", "volume": "54", "author": "J Vieweg", "year": "1994", "unstructured": "Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994;54(7):1760\u20135.", "journal-title": "Cancer Res"}, {"issue": "10", "key": "14_CR121", "first-page": "5211", "volume": "163", "author": "J Shimizu", "year": "1999", "unstructured": "Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163(10):5211\u20138.", "journal-title": "J Immunol"}, {"issue": "9", "key": "14_CR122", "doi-asserted-by": "crossref", "first-page": "4272", "DOI": "10.4049/jimmunol.168.9.4272", "volume": "168", "author": "EY Woo", "year": "2002", "unstructured": "Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168(9):4272\u20136.", "journal-title": "J Immunol"}, {"issue": "2", "key": "14_CR123", "doi-asserted-by": "crossref", "first-page": "1444", "DOI": "10.4049/jimmunol.173.2.1444", "volume": "173", "author": "M Viguier", "year": "2004", "unstructured": "Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173(2):1444\u201353.", "journal-title": "J Immunol"}, {"issue": "2", "key": "14_CR124", "first-page": "606", "volume": "9", "author": "AM Wolf", "year": "2003", "unstructured": "Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9(2):606\u201312.", "journal-title": "Clin Cancer Res"}, {"issue": "12", "key": "14_CR125", "doi-asserted-by": "publisher", "first-page": "1797", "DOI": "10.1016/0959-8049(94)E0159-2", "volume": "30A", "author": "S Vesalainen", "year": "1994", "unstructured": "Vesalainen S, Lipponen P, Talja M, et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A(12):1797\u2013803.", "journal-title": "Eur J Cancer"}, {"issue": "12", "key": "14_CR126", "doi-asserted-by": "publisher", "first-page": "3623", "DOI": "10.1172/JCI25947", "volume": "115", "author": "J Dannull", "year": "2005", "unstructured": "Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623\u201333.", "journal-title": "J Clin Invest"}, {"issue": "5", "key": "14_CR127", "doi-asserted-by": "crossref", "first-page": "419", "DOI": "10.1016/j.urolonc.2005.08.021", "volume": "24", "author": "JW Simons", "year": "2006", "unstructured": "Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24(5):419\u201324.", "journal-title": "Urol Oncol"}, {"key": "14_CR128", "unstructured": "Small E, Higano C, Corman J. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004;22(14s). Abstract 4565", "DOI": "10.1200/jco.2004.22.90140.4565", "doi-asserted-by": "crossref"}], "container-title": ["Targeted Cancer Therapy", "Current Clinical Oncology\u2122"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-60327-424-1_14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 8]], "date-time": "2019-05-08T18:49:37Z", "timestamp": 1557341377000}, "score": 22.16202, "issued": {"date-parts": [[null]]}, "ISBN": ["9781603274234", "9781603274241"], "references-count": 128, "URL": "http://dx.doi.org/10.1007/978-1-60327-424-1_14", "relation": {"cites": []}}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}